1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;
68:7–30.
2. Vallet S, Pahernik S, Hofner T, Tosev G, Hadaschik B, Duensing S, et al.
Efficacy of targeted treatment beyond third-line therapy in metastatic
kidney cancer: retrospective analysis from a large-volume cancer center. Clin
Genitourin Cancer. 2015;13:E145–52.
3. Lin P, Ren H, Zhang Y, Zhou Z. Fifteen-gene expression based model
predicts the survival of clear cell renal cell carcinoma. Medicine 2018;97:e
11839.
4. Chang W, Gao X, Han Y, Du Y, Liu Q, Wang L, et al. Gene expression
profiling-derived immunohistochemistry signature with high prognostic
value in colorectal carcinoma. Gut. 2014;63:1457–67.
5. Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, et al.
Nomogram predicting prostate cancer-specific mortality for men with
biochemical recurrence after radical prostatectomy. Eur Urol. 2015;67:1160–7.
6. Massari F, Bria E, Ciccarese C, Munari E, Modena A, Zambonin V, et al.
Prognostic value of beta-tubulin-3 and c-Myc in muscle invasive urothelial
carcinoma of the bladder. Plos One. 2015;10:e0127908.
7. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al.
Concordance among Gene-Expression– Based Predictors for Breast Cancer.
N Engl J Med. 2006;355:560–9.
8. Isono T, Chano T, Kitamura A, Yuasa T. Glucose deprivation induces G2/M
transition-arrest and cell death in N-GlcNAc2-modified protein-producing
renal carcinoma cells. PLoS One. 2014;9:e96168.
9. Isono T, Chano T, Yonese J, Yuasa T. Therapeutic inhibition of mitochondrial
function induces cell death in starvation-resistant renal cell carcinomas. Sci
Rep. 2016;6:25669.
Page 11 of 11
10. Yoshida T, Kageyama S, Isono T, Yuasa T, Kushima R, Kawauchi A, et al.
Superoxide dismutase 2 expression can predict prognosis of renal cell
carcinoma patients. Cancer Biomark. 2018;22:755–61.
11. Isono T, Chano T, Yoshida T, Makino A, Ishida S, Suzaki M, et al. ADPribosylation factor-like 4C is a predictive biomarker of poor prognosis in
patients with renal cell carcinoma. Am J Cancer Res. 2019;9:415–23.
12. Pu Z, Wang Q, Xie H, Wang G, Hao H. Clinicalpathological and prognostic
significance of survivin expression in renal cell carcinoma: a meta-analysis.
Oncotarget. 2017;8:19825–33.
13. Gao Z, Zhang D, Duan Y, Yan L, Fan Y, Fang Z, et al. A five-gene signature
predicts overall survival of patients with papillary renal cell carcinoma. PLoS
One. 2019;14:e0211491.
14. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO
classification of tumours of the urinary system and male genital organs-part
a: renal, penile, and testicular tumours. Eur Urol. 2016;70:93–105.
15. James DB. TNM Classification of Malignant Tumours. 8th ed. New Jersey:
Wiley-Blackwell; 2016.
16. Fujii S, Matsumoto S, Nojima S, Morii E, Kikuchi A. Arl4c expression in
colorectal and lung cancers promotes tumorigenesis and may represent a
novel therapeutic target. Oncogene. 2015;34:4834–44.
17. Hu Q, Masuda T, Sato K, Tobo T, Nambara S, Kidogami S, et al. Identification
of ARL4C as a peritoneal dissemination-associated gene and its clinical
significance in gastric cancer. Ann Surg Oncol. 2018;25:745–53.
18. Wakinoue S, Chano T, Amano T, Isono T, Kimura F, Kushima R, et al. ADPribosylation factor-like 4C predicts worse prognosis in endometriosisassociated ovarian cancers. Cancer Biomark. 2019;24:223–9.
19. Wondergem B, Zhang Z, Huang D, Ong CK, Koeman J, Hof DV, et al.
Expression of the PTTG1 oncogene is associated with aggressive clear cell
renal cell carcinoma. Cancer Res. 2012;72:4361–7431.
20. Loo SY, Hirpara JL, Pandey V, Tan TZ, Yap CT, Lobie PE, et al. Manganese
superoxide dismutase expression regulates the switch between an epithelial
and a mesenchymal-like phenotype in breast carcinoma. Antioxid Redox
Signal. 2016;25:283–99.
21. Han M, Xu R, Wang S, Yang N, Ni S, Zhang Q, et al. Six-transmembrane
epithelial antigen of prostate 3 predicts poor prognosis and promotes
glioblastoma growth and invasion. Neoplasia. 2018;20:543–54.
22. Isobe T, Baba E, Arita S, Komoda M, Tamura S, Shirakawa T, et al. Human
STEAP3 maintains tumor growth under hypoferric condition. Exp Cell Res.
2011;317:2582–91.
23. Kimura K, Matsumoto S, Harada T, Morii E, Nagatomo I, Shintani Y, et al.
ARL4C is associated with initiation and progression of lung adenocarcinoma
and represents a therapeutic target. Cancer Sci. 2019;111:951–3.
24. Harada T, Matsumoto S, Hirota S, Kimura H, Fujii S, Kasahara Y, et al.
Chemically modified antisense oligonucleotide against ARL4C inhibits
primary and metastatic liver tumor growth. Mol Cancer Ther. 2019;18:602–12.
25. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al.
EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67:913–24.
26. Bhaoighill MN, Dunlop EA. Mechanistic target of rapamycin inhibitors: successes
and challenges as cancer therapeutics. Cancer Drug Resist. 2019;2:1069–85.
27. Wu H, Ding Z, Hu D, Sun F, Dai C, Xie J, et al. Central role of lactic acidosis
in cancer cell resistance to glucose deprivation-induced cell death. J Pathol.
2012;227:189–99.
28. Emami Riedmaier A, Fisel P, Nies AT, Schaeffeler E, Schwab M. Metformin
and cancer: from the old medicine cabinet to pharmacological pitfalls and
prospects. Trends Pharmacol Sci. 2013;34:126–35.
29. Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment
for cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27:2184–95.
30. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. Metformin use is
associated with better survival of diabetic patients with pancreatic cancer.
Clin Cancer Res. 2012;18:2905–12.
31. Cao X, Wen ZS, Wang XD, Li Y, Liu KY, Wang X. The clinical effect of
metformin on the survival of lung cancer patients with diabetes: a
comprehensive systematic review and meta-analysis of retrospective
studies. J Cancer. 2017;8:2532–41.
32. Xiao Y, Zheng L, Mei Z, Xu C, Liu C, Chu X, et al. The impact of metformin
use on survival in prostate cancer: a systematic review and meta-analysis.
Oncotarget. 2017;8:100449–58.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
...
論文の公開元へ
